What are biomarkers, and why do they matter?
Explain biomarkers in plain terms and show how biomarker testing can open doors to targeted trials worth asking your team about.
What a biomarker actually is
A biomarker is simply a feature of your cancer that can be measured — most often a gene change, a protein, or another substance found in your tumor or blood. Doctors read these features to understand your cancer more precisely and to help choose treatments.
You may have heard some of them by name. HER2, EGFR, and PD-L1 are all biomarkers. Each one is a specific detail about how a cancer behaves. And here is the key idea: every person’s cancer carries its own pattern of biomarkers, almost like a fingerprint. Two people with the same type of cancer can have very different profiles underneath.
That fingerprint is powerful information, because some treatments are designed to target one specific feature.
How testing reveals them
Finding your biomarkers takes a test. It goes by a few names — biomarker testing, molecular testing, or genomic profiling — but they all mean the same basic thing: looking closely at a sample of your cancer to see which features it carries.
The sample usually comes from a piece of your tumor, and sometimes from a blood draw. A lab then reads the sample and reports what it finds. Those results become a map that you and your care team can use to guide decisions.
Why this opens doors to trials
Many of today’s most promising trials are targeted — they are built for cancers that carry a particular biomarker. A trial might be studying a drug that works specifically against an EGFR change, or one that responds to PD-L1. If your cancer has that feature, you may be a candidate for that trial.
In other words, a biomarker result can be a key. It can unlock trials that would never show up if you only searched by cancer type and stage. Without the test, those doors stay hidden — not because you don’t qualify, but because no one knows to look.
Bring it to your team
You do not need to memorize biomarker names or interpret lab reports yourself — that is your care team’s job. Your part is simpler: make sure the question gets asked.
Knowing whether you’ve had testing, and what it showed, helps you and your team match you to the right options. And if some results are missing or still pending, that’s okay — it just becomes one more thing to ask about as you explore. Not having every answer yet never means you have to stop looking.
Key takeaways
- A biomarker is a measurable feature of your cancer, like a gene change or protein, that guides treatment.
- Common examples include HER2, EGFR, and PD-L1, though every cancer has its own pattern.
- Biomarker testing can match you to targeted trials built for cancers with your specific profile.
- It is worth asking your care team whether you have had biomarker or molecular testing, and what it showed.
Common questions
How do I know if I have had biomarker testing?
The clearest way is to ask your care team directly. You might say, "Has my cancer had biomarker or molecular testing, and can we go over the results?" These tests are usually done on a sample of your tumor or sometimes your blood. Knowing what was found can help you and your team spot trials that target your cancer's specific features.
Does a biomarker result guarantee I can join a targeted trial?
Not by itself. A matching biomarker can make you a candidate for a trial, but each trial still has its own full set of criteria beyond the biomarker. Think of it as one important key that can open a door, not a guarantee the door is the right fit. Your team can help you check the rest.
This lesson is general education, not medical advice. It doesn't diagnose or treat, and it can't tell you whether a specific trial is right for you — that's a conversation for you, your care team, and the trial's own screening. Always confirm details on ClinicalTrials.gov and with your doctor.
Sources
- Biomarker Testing for Cancer Treatment — National Cancer Institute
- What Are Cancer Clinical Trials? — National Cancer Institute